Compugen Ltd.

NasdaqCM:CGEN 주식 보고서

시가총액: US$150.4m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Compugen 관리

관리 기준 확인 3/4

Compugen's CEO는 Anat Cohen-Dayag, Jun2009 에 임명되었습니다 의 임기는 10.33 년입니다. 총 연간 보상은 $ 1.46M, 32.7% 로 구성됩니다. 32.7% 급여 및 67.3% 보너스(회사 주식 및 옵션 포함). 는 $ 104.38K 가치에 해당하는 회사 주식의 0.063% 직접 소유합니다. 104.38K. 경영진과 이사회의 평균 재임 기간은 각각 4.6 년과 7 년입니다.

주요 정보

Anat Cohen-Dayag

최고 경영자

US$1.5m

총 보상

CEO 급여 비율32.7%
CEO 임기15yrs
CEO 소유권0.06%
경영진 평균 재임 기간4.6yrs
이사회 평균 재임 기간7yrs

최근 관리 업데이트

Recent updates

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27
Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28
Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08
Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Compugen: Speculative Play For Immuno-Oncology Exposure

Nov 07

Compugen Q3 Earnings Preview

Nov 04

CEO 보상 분석

Anat Cohen-Dayag 의 보수는 Compugen 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$17m

Dec 31 2023US$1mUS$479k

-US$19m

Sep 30 2023n/an/a

-US$32m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$479k

-US$34m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$1mUS$498k

-US$34m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$36m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$1mUS$453k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$941kUS$395k

-US$27m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$854kUS$391k

-US$23m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$29m

Mar 31 2018n/an/a

-US$28m

Dec 31 2017US$740kUS$392k

-US$37m

보상 대 시장: Anat 의 총 보상 ($USD 1.46M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.62M ).

보상과 수익: 회사가 수익성이 없는 동안 Anat 의 보상이 증가했습니다.

CEO

Anat Cohen-Dayag (57 yo)

15yrs

테뉴어

US$1,464,448

보상

Dr. Anat Cohen-Dayag, Ph D., served as an Independent Director at Gamida Cell Ltd since January 28, 2022 until March 2023. She serves as Director at has been Chief Executive Officer and President at Compug...

리더십 팀

이름위치테뉴어보상소유권
Anat Cohen-Dayag
CEO, President & Director15yrsUS$1.46m0.063%
$ 94.3k
Eran Ophir
Chief Scientific Officer4.3yrsUS$540.64k데이터 없음
Zurit Levine
Senior Vice President of Technology Innovation6.4yrsUS$532.26k데이터 없음
Pierre Ferre
Vice President of Preclinical Development3.2yrsUS$570.40k데이터 없음
Alberto Sessa
Chief Financial Officer1.6yrs데이터 없음데이터 없음
Yvonne Naughton
Head of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음
Eran Dor
General Counsel & Corporate Secretary5.4yrs데이터 없음데이터 없음
Dorit Amitay
Vice President of Human Resources17.4yrs데이터 없음데이터 없음
Yaron Turpaz
Senior VP & Senior Advisor of Data and Informatics Solutions4.6yrs데이터 없음데이터 없음
Rivka Schwartz
Vice President Research and Discoveryno data데이터 없음데이터 없음
Michelle Mahler
Chief Medical Officerless than a year데이터 없음데이터 없음

4.6yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: CGEN 의 관리팀은 경험 ( 4.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Anat Cohen-Dayag
CEO, President & Director10.3yrsUS$1.46m0.063%
$ 94.3k
Nils Lonberg
Member of Scientific Advisory Board3.8yrs데이터 없음데이터 없음
Sanford Zweifach
Independent Director6yrs데이터 없음데이터 없음
Howard Soule
Member of Scientific Advisory Board10.8yrs데이터 없음데이터 없음
Gilead Halevy
Independent Director6yrs데이터 없음데이터 없음
Paul Sekhri
Independent Chairman of the Board6.7yrs데이터 없음데이터 없음
Kinneret Livnat-Savitzky
Independent Director6yrs데이터 없음데이터 없음
Drew Pardoll
Chairman of Scientific Advisory Board10.4yrs데이터 없음데이터 없음
Antoni Ribas
Member of Scientific Advisory Board10.8yrs데이터 없음데이터 없음
Eran Perry
Independent Director4.9yrs데이터 없음데이터 없음
Iain McInnes
Member of Scientific Advisory Board10.8yrs데이터 없음데이터 없음
Miriam Merad
Member of Scientific Advisory Board7.3yrs데이터 없음데이터 없음

7.0yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: CGEN 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.